Lucid Diagnostics Q2 FY26 revenue rises 25% to USD 1.5 million
LUCD•Business updates
Business updates included a VA contract award, a first positive lab benefit manager coverage policy in July 2026, and USD 16.8 million net proceeds from an April equity offering.
Q2 revenue and expenses
Lucid Diagnostics posted Q2 revenue of USD 1.5 million, up 25% from a year earlier.
Sales and marketing expense climbed to USD 5.8 million from USD 4 million on higher compensation and personnel-related costs.
General and administrative expense edged up to USD 5.8 million from USD 5.6 million, reflecting higher compensation partly offset by lower financing-related fees.
Cash position and operating use
Cash on hand totaled USD 33.4 million at June 30, 2026; the company used USD 23.4 million of cash in operations in H1.
